{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:41Z","timestamp":1789972121337,"version":"4.0.1"},"reference-count":163,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.beem.2014.09.003","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T03:54:35Z","timestamp":1410839675000},"page":"809-834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Efficacy and safety of currently marketed anti-osteoporosis medications"],"prefix":"10.1016","volume":"28","author":[{"given":"J.Y.","family":"Reginster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Neuprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dardenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Beaudart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Emonts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bruyere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2014.09.003_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrrheum.2009.260","article-title":"Osteoporosis: impact on health and economics","volume":"6","author":"Harvey","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.beem.2014.09.003_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2012.11.018","article-title":"Treatment of osteoporosis in men","volume":"53","author":"Kaufman","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"Kanis","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-010-9420-x","article-title":"Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate and denosumab) on bone quality: a systematic review","volume":"87","author":"Gallacher","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2014.09.003_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11587570-000000000-00000","article-title":"Antifracture efficacy of currently available therapies for postmenopausal osteoporosis","volume":"71","author":"Reginster","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.beem.2014.09.003_bib6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00198-010-1223-4","article-title":"Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club","volume":"21","author":"Body","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00198-004-1812-1","article-title":"Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club","volume":"16","author":"Boonen","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators \u2013 mechanisms of action and application to clinical practice","volume":"348","author":"Riggs","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib9","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1359\/jbmr.1998.13.11.1747","article-title":"Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial","volume":"13","author":"Lufkin","year":"1998","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"J\u00a0Med Am Assoc"},{"key":"10.1016\/j.beem.2014.09.003_bib11","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archinte.162.10.1140","article-title":"Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteopororis","volume":"162","author":"Maricic","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2014.09.003_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","article-title":"Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial","volume":"33","author":"Delmas","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s001980200125","article-title":"Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study","volume":"13","author":"Siris","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S8756-3282(03)00200-X","article-title":"Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation Trial","volume":"33","author":"Kanis","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib15","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.003_bib16","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"J\u00a0Med Am Assoc"},{"key":"10.1016\/j.beem.2014.09.003_bib17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jama.287.7.847","article-title":"MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE randomized trial","volume":"287","author":"Barrett-Connor","year":"2002","journal-title":"J\u00a0Med Am Assoc"},{"key":"10.1016\/j.beem.2014.09.003_bib18","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.beem.2014.09.003_bib19","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study","volume":"20","author":"Siris","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","article-title":"Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women","volume":"30","author":"Neele","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib22","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"J\u00a0Med Am Assoc"},{"key":"10.1016\/j.beem.2014.09.003_bib23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00198-011-1775-y","article-title":"Individualizing osteoporosis therapy","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2474-11-130","article-title":"Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis","volume":"11","author":"Christiansen","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.beem.2014.09.003_bib25","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","article-title":"Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries and breast from a randomized controlled trial in osteoporotic postmenopausal women","volume":"16","author":"Archer","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.beem.2014.09.003_bib26","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib27","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","article-title":"Bazedoxifene reduces vertebral and clinical fractures inpostmenopausal women at high risk assessed with FRAX","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bone.2010.06.009","article-title":"A\u00a0meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX","volume":"47","author":"Kanis","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib29","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s00198-013-2341-6","article-title":"The effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX","volume":"24","author":"Kaufman","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","article-title":"Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.maturitas.2013.06.008","article-title":"Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study","volume":"76","author":"Palacios","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.beem.2014.09.003_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/CIA.S15711","article-title":"Efficacy and safety of bazedoxifene for postmenopausal osteoporosis","volume":"6","author":"Kawate","year":"2011","journal-title":"J\u00a0Clin Interv Aging"},{"key":"10.1016\/j.beem.2014.09.003_bib33","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/gme.0b013e3181a7fb1e","article-title":"The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis","volume":"16","author":"Harvey","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.beem.2014.09.003_bib34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-010-1302-6","article-title":"Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial","volume":"22","author":"de Villiers","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3109\/13697137.2012.717994","article-title":"Effects of bazedoxifene\/conjugated estrogens on endometrial safety and bone in postmenopausal women","volume":"16","author":"Mirkin","year":"2013","journal-title":"Climateric"},{"key":"10.1016\/j.beem.2014.09.003_bib36","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1185\/03007995.2014.890927","article-title":"Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene","volume":"30","author":"Reginster","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.beem.2014.09.003_bib37","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib38","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2014.09.003_bib39","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"J\u00a0Med Am Assoc"},{"key":"10.1016\/j.beem.2014.09.003_bib40","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jama.1997.03540380073035","article-title":"Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups","volume":"277","author":"Karpf","year":"1997","journal-title":"J\u00a0Med Am Assoc"},{"key":"10.1016\/j.beem.2014.09.003_bib41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2014.09.003_bib42","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib43","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"J\u00a0Med Am Assoc"},{"key":"10.1016\/j.beem.2014.09.003_bib44","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"De Groen","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib45","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging Milano"},{"key":"10.1016\/j.beem.2014.09.003_bib46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1185\/03007990802648903","article-title":"In\u00a0vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US","volume":"25","author":"Dansereau","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.beem.2014.09.003_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00296-009-0940-5","article-title":"Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis","volume":"30","author":"Ringe","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.beem.2014.09.003_bib48","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"J\u00a0Med Am Assoc"},{"key":"10.1016\/j.beem.2014.09.003_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib51","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","article-title":"Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old","volume":"52","author":"Boonen","year":"2004","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.beem.2014.09.003_bib52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2014.09.003_bib53","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib54","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.beem.2014.09.003_bib55","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10067-007-0824-6","article-title":"Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension","volume":"27","author":"Stakkestad","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.beem.2014.09.003_bib56","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2014.09.003_bib57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","article-title":"Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data","volume":"20","author":"Cranney","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib58","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2008.10.052","article-title":"Ibandronate dose response is associated with increase in bone mineral density and reductions in clinical fractures: results of a meta-analysis","volume":"44","author":"Sebba","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib59","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bone.2009.01.002","article-title":"Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of Ibandronate Efficacy (VIBE) database fracture study","volume":"44","author":"Harris","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib60","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00198-013-2518-z","article-title":"Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies","volume":"25","author":"Miller","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.0954-6820.2003.01258.x","article-title":"Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes","volume":"255","author":"Boonen","year":"2004","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.beem.2014.09.003_bib62","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/030079908X253889","article-title":"Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study","volume":"24","author":"Miller","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.beem.2014.09.003_bib63","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib64","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib65","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1359\/jbmr.090704","article-title":"Potential mediators of the mortality reduction with zoledronic acid after hip fracture","volume":"25","author":"Colon-Emeric","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib66","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2008.12.004","article-title":"Safety of bisphosphonates in the treatment of osteoporosis","volume":"122","author":"Recker","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002018-200932030-00004","article-title":"Bisphosphonates and atrial fibrillation: systematic review and meta-analysis","volume":"32","author":"Loke","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.beem.2014.09.003_bib68","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ki.2008.193","article-title":"Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women","volume":"74","author":"Boonen","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2014.09.003_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.1744","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib70","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2012-2868","article-title":"Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams","volume":"98","author":"Reid","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.003_bib71","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2106\/JBJS.G.00864","article-title":"Low incidence of anti-osteoporosis treatment after hip fracture","volume":"90","author":"Rabenda","year":"2008","journal-title":"J\u00a0Bone Jt Surg"},{"key":"10.1016\/j.beem.2014.09.003_bib72","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4158\/EP.12.5.522","article-title":"Medication persistence with weekly versus daily doses of orally administered bisphosphonates","volume":"12","author":"Ettinger","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1016\/j.beem.2014.09.003_bib73","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00198-013-2576-2","article-title":"Comparative gastronintetinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis","volume":"25","author":"Tadrous","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtraochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib75","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.bone.2013.02.004","article-title":"Proposed pathogenesis for atypical femoral fractures: lessons from material research","volume":"55","author":"Ettinger","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib76","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib77","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-010-1453-5","article-title":"Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report","volume":"22","author":"Rizzoli","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib78","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1302\/0301-620X.94B3.27999","article-title":"Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals","volume":"94","author":"Thompson","year":"2012","journal-title":"J\u00a0Bone Joint Surg Br"},{"key":"10.1016\/j.beem.2014.09.003_bib79","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1210\/jc.2010-2520","article-title":"Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy","volume":"96","author":"Gomberg","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.003_bib80","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1210\/jc.2011-0593","article-title":"Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide","volume":"96","author":"Carvalho","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.003_bib81","first-page":"166","article-title":"Healing of subtrochanteric atypical fractures after strontium ranelate treatment","volume":"9","author":"Negri","year":"2012","journal-title":"Clin Cases Miner Bone Metabol"},{"key":"10.1016\/j.beem.2014.09.003_bib82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.beem.2014.09.003_bib83","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(06)70726-4","article-title":"Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment","volume":"7","author":"Migliorati","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2014.09.003_bib84","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?","volume":"45","author":"Lesclous","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib85","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bone.2008.01.003","article-title":"Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis","volume":"42","author":"Rizzoli","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib86","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Sb","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2014.09.003_bib87","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncponc0688","article-title":"Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease","volume":"4","author":"Dunstan","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.beem.2014.09.003_bib89","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00198-009-1003-1","article-title":"The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK","volume":"24","author":"Cooper","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib90","doi-asserted-by":"crossref","first-page":"c246","DOI":"10.1136\/bmj.c246","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"340","author":"Khan","year":"2010","journal-title":"Br Med J"},{"key":"10.1016\/j.beem.2014.09.003_bib91","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14219\/jada.archive.2008.0017","article-title":"Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial","volume":"139","author":"Grbic","year":"2008","journal-title":"J\u00a0Am Dent Assoc"},{"key":"10.1016\/j.beem.2014.09.003_bib92","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00223-011-9499-8","article-title":"Adverse reactions and drug-drug interactions in the management of women with postmenopauxal osteoporosis","volume":"89","author":"Rizzoli","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2014.09.003_bib93","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular disease","volume":"292","author":"Hofbauer","year":"2004","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.beem.2014.09.003_bib94","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00223-004-0074-4","article-title":"Increased RANKL\/OPG mRNA ratio in iliac bone biopsies from women with hip fractures","volume":"76","author":"Abdallah","year":"2005","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2014.09.003_bib95","first-page":"1","article-title":"Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"14","author":"Brown","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib96","first-page":"756","article-title":"FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib97","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib98","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.003_bib99","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib100","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib101","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jbmr.1606","article-title":"Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX","volume":"27","author":"McCloskey","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib102","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib103","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib104","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomized trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2014.09.003_bib105","first-page":"1793","article-title":"Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease","volume":"33","author":"Sivolella","year":"2013","journal-title":"Anti-Cancer Res"},{"key":"10.1016\/j.beem.2014.09.003_bib106","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jcms.2013.05.038","article-title":"Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection","volume":"41","author":"Otto","year":"2013","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.beem.2014.09.003_bib107","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00198-013-2437-z","article-title":"Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab","volume":"25","author":"Neuprez","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/17453674.2013.854668","article-title":"Atypical femoral fractures bilaterally in patient receiving denosumab","volume":"85","author":"Drampalos","year":"2014","journal-title":"Acta Orthop"},{"key":"10.1016\/j.beem.2014.09.003_bib109","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4158\/EP12367.CR","article-title":"A\u00a0case of an unusual subtrochanteric fracture in a patient receiving denosumab","volume":"19","author":"Paparodis","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.beem.2014.09.003_bib110","series-title":"Protelos: EPAR \u2013 scientific discussion","author":"EMA","year":"2005"},{"key":"10.1016\/j.beem.2014.09.003_bib111","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00198-010-1369-0","article-title":"How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis","volume":"22","author":"Marie","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib112","first-page":"2060","article-title":"Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis \u2013 a 2-year randomized placebo controlled trial","volume":"87","author":"Meunier","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.003_bib113","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib114","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","article-title":"Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) Study","volume":"90","author":"Reginster","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.003_bib115","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00198-008-0825-6","article-title":"Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis","volume":"20","author":"Meunier","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib116","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1742-1241.2006.01249.x","article-title":"Strontium ranelate in the prevention of osteoporotic fractures","volume":"61","author":"Reginster","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.beem.2014.09.003_bib117","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bone.2009.08.004","article-title":"Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years","volume":"45","author":"Reginster","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib118","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00198-011-1847-z","article-title":"Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis","volume":"23","author":"Reginster","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib119","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1359\/jbmr.060101","article-title":"Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors","volume":"21","author":"Roux","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib120","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1136\/ard.2008.094516","article-title":"Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis","volume":"67","author":"Roux","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.beem.2014.09.003_bib121","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1359\/jbmr.060404","article-title":"Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older","volume":"21","author":"Seeman","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib122","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1210\/jc.2006-2758","article-title":"Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate","volume":"92","author":"Bruy\u00e8re","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.003_bib123","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1185\/030079907X242818","article-title":"Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate","volume":"23","author":"Bruy\u00e8re","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.beem.2014.09.003_bib124","series-title":"Question and answers on the safety of Protelos\/Osseor (strontium ranelate)","author":"EMEA","year":"2007"},{"key":"10.1016\/j.beem.2014.09.003_bib125","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14740338.2013.793669","article-title":"Safety concerns with the long-term management of osteoporosis","volume":"12","author":"Reginster","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.beem.2014.09.003_bib126","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1185\/03007995.2012.663750","article-title":"Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF)","volume":"28","author":"Cooper","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.beem.2014.09.003_bib127","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2125.2008.03273.x","article-title":"Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions","volume":"66","author":"Grosso","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.beem.2014.09.003_bib128","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00198-009-1050-7","article-title":"Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database","volume":"21","author":"Breart","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib129","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00198-013-2265-1","article-title":"Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate","volume":"24","author":"Cacoub","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib130","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00198-009-1097-5","article-title":"Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity","volume":"21","author":"Musette","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib131","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000069956","article-title":"Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update","volume":"206","author":"Tas","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.beem.2014.09.003_bib132","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00198-013-2583-3","article-title":"Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice","volume":"25","author":"Donneau","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib133","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-013-2582-4","article-title":"Ischaemic cardiac events and use of strontium ranelate in postmonopausal osteoporosis: a nested case-control study in the CPRD","volume":"25","author":"Cooper","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib134","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00198-013-2469-4","article-title":"Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate","volume":"25","author":"Abrahamsen","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib135","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2014-205283","article-title":"Une of strontium ranelate and risk of acute coronary syndrome: cohort study","volume":"73","author":"Svanstr\u00f6m","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.beem.2014.09.003_bib136","first-page":"97","article-title":"Bone forming agents for the management of osteoporosis","volume":"56","author":"Reginster","year":"2014","journal-title":"Panminerva Med"},{"key":"10.1016\/j.beem.2014.09.003_bib137","series-title":"European Medicines Agency recommends that Protelos\/Osseor remain available but with further restrictions","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.beem.2014.09.003_bib138","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1007\/BF03194365","article-title":"Parathyroid hormone in the treatment of involutional osteoporosis: back to the future","volume":"7","author":"Reginster","year":"1997","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.003_bib139","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib141","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide (recombinant human parathyroid hormone (1\u201334)) in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2014.09.003_bib142","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib143","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bone.2006.02.003","article-title":"Fracture risk reduction during treatment with teriparatide is independent of pre-treatment bone turnover","volume":"39","author":"Delmas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib144","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00223-009-9299-6","article-title":"Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)","volume":"85","author":"Langdahl","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2014.09.003_bib145","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00223-012-9590-9","article-title":"Effectiveness of teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS)","volume":"90","author":"Walsh","year":"2012","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2014.09.003_bib146","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/1471-2474-14-251","article-title":"Effective osteoporosis treatement with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis : the European Forsteo Observational Study","volume":"14","author":"Ljunggren","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.beem.2014.09.003_bib147","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2014.09.003_bib148","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Treatment of osteoporosis with parathyroid hormone study group","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2014.09.003_bib149","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1345\/aph.1G146","article-title":"Parathyroid hormone (1\u201384) and treatment of osteoporosis","volume":"39","author":"Shrader","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.beem.2014.09.003_bib150","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2014.09.003_bib151","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized Teriparatide [human parathyroid hormone (PTH) 1\u201334] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.003_bib152","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00774-013-0505-2","article-title":"Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial","volume":"32","author":"Nakano","year":"2014","journal-title":"J\u00a0Bone Miner Metab"},{"key":"10.1016\/j.beem.2014.09.003_bib153","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00223-013-9777-8","article-title":"Once-weekly injection of low-dose teriparatide (28.2 \u03bcg) reduced the risk of vertebral fracture in patients with primary osteoporosis","volume":"94","author":"Fujita","year":"2014","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2014.09.003_bib154","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/jc.2009-0358","article-title":"Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women","volume":"95","author":"Cosman","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2014.09.003_bib155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2012.11.045","article-title":"Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1\u201331)NH(2)] in postmenopausal women with osteoporosis","volume":"53","author":"Henriksen","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib156","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib157","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.003_bib158","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib159","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2014.09.003_bib160","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2014.09.003_bib161","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.bone.2012.10.006","article-title":"Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy","volume":"52","author":"Chiang","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.003_bib162","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/gme.0b013e318260143d","article-title":"Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report","volume":"19","author":"Huang","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.beem.2014.09.003_bib163","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00198-011-1882-9","article-title":"Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws","volume":"23","author":"Kwon","year":"2012","journal-title":"Osteoporos Int"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14001043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14001043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:49:54Z","timestamp":1761497394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X14001043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":163,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1521690X14001043"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2014.09.003","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of currently marketed anti-osteoporosis medications","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2014.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}